Medpace (NASDAQ:MEDP) Releases Earnings Results, Beats Expectations By $0.75 EPS

Medpace (NASDAQ:MEDP) released its quarterly earnings data on Monday. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75, Briefing.com reports. Medpace had a net margin of 15.92% and a return on equity of 65.98%. The business had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter last year, the company earned $2.27 EPS. The company’s revenue for the quarter was up 17.7% compared to the same quarter last year. Medpace updated its FY24 guidance to $10.79-11.47 EPS and its FY 2024 guidance to 10.790-11.470 EPS.

Medpace Stock Up 8.2 %

NASDAQ:MEDP opened at $407.15 on Wednesday. Medpace has a 12 month low of $187.03 and a 12 month high of $419.42. The firm has a market cap of $12.61 billion, a price-to-earnings ratio of 41.50, a P/E/G ratio of 1.99 and a beta of 1.38. The company’s 50 day moving average is $397.68 and its 200-day moving average is $323.14.

Insider Activity

In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Ashley M. Keating sold 250 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total value of $102,467.50. Following the sale, the director now owns 250 shares in the company, valued at $102,467.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock valued at $76,651,647 over the last 90 days. 20.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and increased their price objective for the stock from $340.00 to $450.00 in a report on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. Robert W. Baird raised their target price on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research note on Wednesday, February 14th. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and raised their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $395.60.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.